Eszter Lazar-Molnar
No Rating Available
(Learn About Our Rating System)

Eszter Lazar-Molnar, PhD, D(ABMLI), F(ACHI)

Languages spoken: Hungarian, English

Dr. Lazar-Molnar is an Associate Professor in the Department of Pathology at the University of Utah School of Medicine. She is the director of the Histocompatibility and Immunogenetics laboratory at University of Utah Health, and medical director in the Immunology division at ARUP Laboratories.

She is board certified by the American Board of Medical Laboratory Immunology (ABMLI), and is a Fellow of the American College of Histocompatibility and Immunogenetics (ACHI).

Dr. Lazar-Molnar’s primary interest is diagnostic laboratory immunology, including transplantation testing for pre- and post-transplant monitoring, HLA-disease, and HLA-pharmacogenetic associations, and test interference by monoclonal antibody therapeutics.

Specialties

Board Certification

American College of Histocompatibility & Immunogenetics (ACHI)
American Board of Medical Laboratory Immunology

Dr. Lazar-Molnar is an Associate Professor in the Department of Pathology at the University of Utah School of Medicine. She is the director of the Histocompatibility and Immunogenetics laboratory at University of Utah Health, and medical director in the Immunology division at ARUP Laboratories.

She is board certified by the American Board of Medical Laboratory Immunology (ABMLI), and is a Fellow of the American College of Histocompatibility and Immunogenetics (ACHI).

Dr. Lazar-Molnar’s primary interest is diagnostic laboratory immunology, including transplantation testing for pre- and post-transplant monitoring, HLA-disease, and HLA-pharmacogenetic associations, and test interference by monoclonal antibody therapeutics.

Board Certification and Academic Information

Academic Departments Pathology -Associate Professor (Clinical)
Board Certification
American College of Histocompatibility & Immunogenetics (ACHI)
American Board of Medical Laboratory Immunology

Education history

Doctoral Training Pharmacy - University of Medicine and Pharmacy of Târgu Mure¿ Pharm.D.
Doctoral Training Genetics, Cell and Immunobiology - Semmelweis University School of Medicine Ph.D.
Postdoctoral Fellowship Microbiology & Immunology - Albert Einstein College of Medicine Postdoctoral Fellow
Fellowship Immunology - University of Utah Clinical Fellow

Selected Publications

Journal Article

  1. Lázár-Molnár E, Hegyesi H, Tóth S, Falus A (2000). Autocrine and paracrine regulation by cytokines and growth factors in melanoma. Cytokine, 12(6), 547-54.
  2. Szincsák N, Hegyesi H, Hunyadi J, Martin G, Lázár-Molnár E, Kovács P, Rivera E, Falus A, Juhász I (2002). Cimetidine and a tamoxifen derivate reduce tumour formation in SCID mice xenotransplanted with a human melanoma cell line. Melanoma Res, 12(3), 231-40.
  3. Kohidai L, Kovacs P, Lazar-Molnar E, Csaba G (2000). Presence, uptake and localization of an immunoreactively interleukin 6 (IL-6)-like molecule in Tetrahymena pyriformis. Cell Biol Int, 24(10), 749-55.
  4. Lazar-Molnar E, Almo SC, Nathenson SG (2006). The interchain disulfide linkage is not a prerequisite but enhances CD28 costimulatory function. Cell Immunol, 244(2), 125-9.
  5. Lázár-Molnár E, Delgado J (2016). Immunogenicity Assessment of Tumor Necrosis Factor Antagonists in the Clinical Laboratory. Clinical chemistry, 62(9), 1186-98.
  6. Luo YR, Chakraborty I, Lazar-Molnar E, Wu AHB, Lynch K (2020). Development of Label-Free Immunoassays as Novel Solutions for the Measurement of Monoclonal Antibody Drugs and Antidrug Antibodies. Clinical chemistry, 66(10), 1319-1328.
  7. Pavlov IY, Carper J, Lázár-Molnár E, Delgado J (2016). Clinical laboratory application of a reporter-gene assay for measurement of functional activity and neutralizing antibody response to infliximab. Clinica chimica acta; international journal of clinical chemistry, 453, 147-53.
  8. Yang Y, Wysocki E, Antwi K, Niederkofler E, Leung EKY, Lazar-Molnar E, Yeo K (2018). Development and validation of a targeted affinity-enrichment and LC-MS/MS proteomics approach for the therapeutic monitoring of adalimumab. Clinica chimica acta; international journal of clinical chemistry, 483, 308-314.
  9. Lazar-Molnar E, Tebo A (2015). Autoimmune NMDA receptor encephalitis. Clinica chimica acta; international journal of clinical chemistry, 438, 90-7.
  10. Lázár-Molnár E, Hegyesi H, Pállinger E, Kovács P, Tóth S, Fitzsimons C, Cricco G, Martin G, Bergoc R, Darvas Z, Rivera ES, Falus (2002). Inhibition of human primary melanoma cell proliferation by histamine is enhanced by interleukin-6. European journal of clinical investigation, 32(10), 743-9.
  11. Profaizer T, Pole A, Monds C, Delgado JC, Lázár-Molnár (2020). Clinical utility of next generation sequencing based HLA typing for disease association and pharmacogenetic testing. Human immunology, 81(7), 354-360.
  12. Chattopadhyay K, Lazar-Molnar E, Yan Q, Rubinstein R, Zhan C, Vigdorovich V, Ramagopal UA, Bonanno J, Nathenson SG, Almo S (2009). Sequence, structure, function, immunity: structural genomics of costimulation. Immunological reviews, 229(1), 356-86.
  13. Pavlov IY, Parker RL, Lázár-Molnár E, Strathmann FG, Delgado J (2019). Inductively coupled plasma mass spectrometry assay for quantification of free infliximab in serum. Journal of immunological methods, 470, 33-39.
  14. Lázár-Molnár E, Gácser A, Freeman GJ, Almo SC, Nathenson SG, Nosanchuk J (2008). The PD-1/PD-L costimulatory pathway critically affects host resistance to the pathogenic fungus Histoplasma capsulatum. Proceedings of the National Academy of Sciences of the United States of America, 105(7), 2658-63.
  15. Lázár-Molnár E, Yan Q, Cao E, Ramagopal U, Nathenson SG, Almo S (2008). Crystal structure of the complex between programmed death-1 (PD-1) and its ligand PD-L2. Proceedings of the National Academy of Sciences of the United States of America, 105(30), 10483-8.
  16. Lázár-Molnár E, Chen B, Sweeney KA, Wang EJ, Liu W, Lin J, Porcelli SA, Almo SC, Nathenson SG, Jacobs WR J (2010). Programmed death-1 (PD-1)-deficient mice are extraordinarily sensitive to tuberculosis. Proceedings of the National Academy of Sciences of the United States of America, 107(30), 13402-7.
  17. Arora P, Baena A, Yu KO, Saini NK, Kharkwal SS, Goldberg MF, Kunnath-Velayudhan S, Carreño LJ, Venkataswamy MM, Kim J, Lazar-Molnar E, Lauvau G, Chang YT, Liu Z, Bittman R, Al-Shamkhani A, Cox LR, Jervis PJ, Veerapen N, Besra GS, Porcelli S (2014). A single subset of dendritic cells controls the cytokine bias of natural killer T cell responses to diverse glycolipid antigens. Immunity, 40(1), 105-16.
  18. Horvath B, Heninger E, Hegyesi H, Lazar E, Radvany Z, Szalai C, Darvas Z, Falus (2000). Reciprocal inhibitory interactions between interferon gamma and histamine in melanoma. Inflammation research, 49 Suppl 1, S27-8.
  19. Falus A, Hegyesi H, Lázár-Molnár E, Pós Z, László V, Darvas (2001). Paracrine and autocrine interactions in melanoma: histamine is a relevant player in local regulation. Trends in immunology, 22(12), 648-52.
  20. Ohaegbulam KC, Assal A, Lazar-Molnar E, Yao Y, Zang (2015). Human cancer immunotherapy with antibodies to the PD-1 and PD-L1 pathway. Trends in molecular medicine, 21(1), 24-33.
  21. Vigdorovich V, Ramagopal UA, Lázár-Molnár E, Sylvestre E, Lee JS, Hofmeyer KA, Zang X, Nathenson SG, Almo S (2013). Structure and T cell inhibition properties of B7 family member, B7-H3. Structure (London, England, 21(5), 707-17.
  22. Shi L, Albuquerque PC, Lazar-Molnar E, Wang X, Santambrogio L, Gácser A, Nosanchuk J (2008). A monoclonal antibody to Histoplasma capsulatum alters the intracellular fate of the fungus in murine macrophages. Eukaryotic cell, 7(7), 1109-17.
  23. Ravkov EV, Charlton CM, Barker AP, Hill H, Peterson LK, Slev P, Tebo A, Voelkerding KV, Wittwer CT, Heikal N, Delgado JC, Lázár-Molnár E, Kumánovics (2019). Evaluation of Mass Cytometry in the Clinical Laboratory. Cytometry. Part B, Clinical cytometry, 96(4), 266-274.
  24. Profaizer T, Lázár-Molnár E, Pole A, Delgado JC, Kumánovics (2017). HLA genotyping using the Illumina HLA TruSight next-generation sequencing kits: A comparison. International journal of immunogenetics, 44(4), 164-168.
  25. Scandiuzzi L, Ghosh K, Hofmeyer KA, Abadi YM, Lázár-Molnár E, Lin EY, Liu Q, Jeon H, Almo SC, Chen L, Nathenson SG, Zang (2014). Tissue-expressed B7-H1 critically controls intestinal inflammation. Cell reports, 6(4), 625-32.
  26. Lázár-Molnár E, Scandiuzzi L, Basu I, Quinn T, Sylvestre E, Palmieri E, Ramagopal UA, Nathenson SG, Guha C, Almo S (2017). Structure-guided development of a high-affinity human Programmed Cell Death-1: Implications for tumor immunotherapy. EBioMedicine, 17, 30-44.
  27. Profaizer T, Lázár-Molnár E, Close DW, Delgado JC, Kumánovics (2016). HLA genotyping in the clinical laboratory: comparison of next-generation sequencing methods. HLA, 88(1-2), 14-24.
  28. Willrich MAV, Lazar-Molnar E, Snyder MR, Delgado J (2018). Comparison of clinical laboratory assays for measuring serum infliximab and antibodies for infliximab. The journal of applied laboratory medicine, 2(6), 893-903.
  29. Profaizer T, Dibb K, Bethers H, Monds C, Andreasen J, Delgado JC, Lázár-Molnár (2021). Comparison of Next-Generation Sequencing-Based Human Leukocyte Antigen Typing with Clinical Flow Cytometry and Allele-Specific PCR Melting Assays for HLA-B27 Genotyping. The journal of applied laboratory medicine, 6(5), 1221-1227.
  30. Potter S, Sudarshan D, Lázár-Molnár E, Baker S, Metcalf RA, Lin (2022). Life threatening platelet transfusion refractoriness due to an anamnestic human leukocyte antigen alloantibody response. Transfusion, 62(11), 2161-2162.
  31. Sideris K, Lázár-Molnár E, Kyriakopoulos CP, Taleb I, Hurst D, Ugolini S, Selzman CH, Brinker L, Drakos SG, Tonna JE, Geer L, Goodwin ML, Wever-Pinzon O, Hanff TC, Fang JC, Carter S, Stehlik (2024). Bridge-to-transplant temporary mechanical circulatory support and risk of allosensitization. Clinical transplantation, 38(5), e15330.
  32. Jain D, Pido MTJ, Delgado JC, Willrich MAV, Lázár-Molnár (2023). Comparison of Two Clinical Laboratory Assays for Measuring Serum Adalimumab and Antibodies to Adalimumab. The journal of applied laboratory medicine, 8(6), 1054-1064.
  33. Jain D, Pavlov IY, ¿u'nik S, Delgado JC, Lázár-Molnár (2025). Expanding the clinical utility of reporter gene assay to infliximab biosimilars. Clinica chimica acta; international journal of clinical chemistry, 575, 120337.
  34. Charnaya O, Ishaque T, Hallett A, Morris GP, Coppage M, Schmitz JL, Timofeeva O, Lázár-Molnár E, Zhang A, Krummey S, Hidalgo L, Segev DL, Tambur AR, Massie A (2025). The Impact of HLA-DQ¿ß Heterodimer Mismatch on Living Donor Kidney Allograft Outcomes. Transplantation, 109(4), 720-728.
  35. Al-Rabadi LF, Storey A, Larsen CP, Hassen SI, Revelo MP, Singh RS, Lazar-Molnar E, Jain D, Ibrahim A, Darras F, Salam R, Al-Rabadi A, Wikan N, Redecke V, Talwar M, Haecker H, Beck LH Jr, Caza T (2024). De novo Membranous Nephropathy in Renal Allografts is Associated With Protocadherin FAT1. Kidney international reports, 10(1), 247-251.
  36. Lázár-Molnár E, Truax CM, Eiting MM, Jain D, Hurst D, Zukauckas K, Pearce A, Bergam S, Gardner S, Clayton F, Florido R, Stehlik J, Shah K (2025). First use of imlifidase desensitization in a highly sensitized heart and liver transplant candidate: A case report. Human immunology, 86(5), 111584.
  37. Yamauchi J, Fornadi K, Raghavan D, Jweehan D, Oygen S, Marineci S, Pole A, Jain D, Lazar-Molnar E, Molnar M (2026). Early posttransplant rituximab use in kidney transplant recipients with preexisting donor-specific antibodies. Renal failure, 48(1), 2620179.

Review

  1. Molnar EL, Hegyesi H, Toth S, Darvas Z, Laszlo V, Szalai C, Falus A (2000). Biosynthesis of interleukin-6, an autocrine growth factor for melanoma, is regulated by melanoma-derived histamine. [Review]. Semin Cancer Biol, 10, (1), 25-8.
  2. Lazar-Molnar E, Delgado J (2016). Immunogenicity Assessment of Tumor Necrosis Factor Antagonists in the Clinical Laboratory. Clinical chemistry, 62(9), 1186-98.
  3. Lázár-Molnár E, Delgado J (2019). Implications of Monoclonal Antibody Therapeutics Use for Clinical Laboratory Testing. Clinical chemistry, 65(3), 393-405.
  4. Lazar-Molnar E, Snyder (2018). The Role of Human Leukocyte Antigen in Celiac Disease Diagnostics. Clinics in laboratory medicine, 38(4), 655-668.
  5. Profaizer T, Lazar-Molnar (2020). Cell-Free DNA and its Applications in Laboratory Medicine. ASHI Quarterly, 2020, Volume 44, Number 2, pg22. ASHI Quarterly, 44(2), 22.
  6. Profaizer T, Lazar-Molnar (2022). Quantifying Donor-Derived Cell-Free DNA in Solid Organ Transplant Recipients. ASHI Quarterly, 2022, Volume 46, Number 2. ASHI Quarterly, 46(2),
  7. Lázár-Molnár E, Peterson L (2025). Clinical utility of the lymphocyte proliferation assay, an in vitro functional readout of the adaptive immune response. Journal of immunological methods, 537, 113819.

Book Chapter

  1. Lazar-Molnar (2004). Signal-transduction pathways of histamine receptors.
  2. Kumánovics A, Lazar-Molnar E, Delgado J (2021). The Major Histocompatibility Complex and Disease.
  3. Lazar-Molnar E, Willrich MA, Delgado J (2023). Monoclonal Antibody Therapeutics and Immunogenicity.

Editorial

  1. Delgado JC, Lazar-Molnar (2018). HLA in Transplantation and Beyond. Clinics in laboratory medicine, 38(4), xi-xii.